EurekAlert!

Serono receives FDA approval for Gonal-f RFF Pen to treat infertility

Geneva, Switzerland and Rockland, MA, May 27, 2004 -- Serono, Inc., the US affiliate of Serono (virt-x: SEO and NYSE: SRA), announced today that the United States Food and Drug Administration (FDA) ...
Business Insider

EMD Serono Receives FDA Approval for New GONAL-f® RFF Redi-ject® Pen

ROCKLAND, Mass., Nov. 13, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, received approval for a redesigned version of GONAL ...
Medscape

FDA Drug and Device Approvals: June 3, 2004

The U.S. Food and Drug Administration has approved trospium chloride for the treatment of overactive bladder, a new device that delivers follitropin alpha for infertility, a new indication for ...
Business Wire

EMD Serono Receives FDA Approval for Redesigned Fertility Pen

Gonal-f ® RFF Redi-ject™ (follitropin alfa injection) is indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to ...
Medindia

EMD Serono''s Redesigned Fertility Pen Available for Distribution in US

- Gonal-f® RFF* Redi-ject™ (follitropin alfa injection) was approved for use by the FDA on October 17, 2013 For more information about the GONAL-F ® RFF Redi-ject™, please call Fertility LifeLines at ...
Business Insider

EMD Serono to Present Real-World Data Analyses at the Annual Pacific Coast Reproductive Society Meeting

ROCKLAND, Mass., March 22, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced two new real-world data analyses ...